Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
Professor Jeanne Tie, MBChB, FRACP, MD, Peter MacCallum Cancer Centre, Victoria, Australia, discusses results from the AGITG DYNAMIC-Rectal study, which explored a circulating tumor DNA (ctDNA)-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
The study showed that a ctDNA-guided approach was associated with a reduced rate of adjuvant chemotherapy administration, though the small sample size in the trial does not allow any conclusions to be drawn about the non-inferiority of a ctDNA-guided approach in comparison to standard management.
The data confirms a lower risk of recurrence for patients with undetectable post-operative ctDNA.
Source:
Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract 12
© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
